



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/825,457	04/14/2004	Chih-Ping Liu	55600.8014.US02	8343
79975	7590	06/10/2009	EXAMINER	
King & Spalding LLP P.O. Box 889 Belmont, CA 94002-0889			DANG, IAN D	
			ART UNIT	PAPER NUMBER
			1647	
			MAIL DATE	DELIVERY MODE
			06/10/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/825,457	Applicant(s) LIU ET AL.	
	Examiner IAN DANG	Art Unit 1647	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 06 August 2008.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,3 and 4 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1,3, and 4 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 14 April 2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>05/05/2004</u> . | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1647

DETAILED ACTION

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 08/06/2008 has been entered.

Status of Application, Amendments and/or Claims

The amendments of 06 August 2008 have been entered in full. Claims 2, 3, and 5-11 have been cancelled.

Claims 1, 3, and 4 are under examination.

Claim Objections

Claim 1 is objected to because of the following informalities:

Claim 1 use acronyms without first defining what they represent in the independent claims (see for example, "IFN- γ "). While the claims can reference acronyms, the material presented by the acronym must be clearly set forth at the first use of the acronym.

Appropriate correction is required.

Rejection Maintained

Claim Rejections - 35 USC § 112, First paragraph (Enablement)

The following is a quotation of the first paragraph of 35 U.S.C. 112:

Art Unit: 1647

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1, 3, and 4 remain rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

At pages 3 and 4 of the response filed 08/06/2008, Applicants argue that the antiviral and conserved regions of interferon tau are known based on the references provided in Pontzer and Radhakrishnan. In addition, Applicants argue that peptide fragments of interferon-tau can compete with interferon-alpha interactions for the type I interferon receptor. Finally, Applicants indicate that similar language claim was allowed in the copending application 11/112,368.

Although the Examiner agrees with Applicants that the antiviral and conserved regions of interferon tau are well characterized based on the 2 references by Applicants and that the language claim is appropriate, Applicants are still not enabled for a method for decreasing IFN-gamma blood levels in a subject with elevated IFN-gamma due to the administration of a therapeutic agent for the treatment of multiple sclerosis comprising orally administering an IFN-tau having greater than about 90% sequence identity to SEQ ID NO:2 at a dosage of between 6×10^8 - 5×10^{12} units to decrease the subject's IFN-tau blood level relative to the IFN-gamma blood level in the absence of IFN-tau administration because Applicants have not provided any guidance on how IFN-tau acts in patients and whether the regions of IFN-tau responsible for antiviral activity would be required or responsible for decreasing IFN-gamma blood levels for the treatment of multiple sclerosis.

Art Unit: 1647

While the the references provided by Applicant in Exhibits 1 and 2 disclose that regions of IFN-tau required for antiviral activity (see page 137 of Pontzer et al.) and that conserved regions of IFN-tau are known (see Radhakrishnan et al., paragraph bridging the columns of page 155, especially right column), Applicants have not provided any correlation between the antiviral and conserved regions of IFN-tau and their activities in reducing IFN-gamma blood levels in patient for the treatment of MS. If Applicants can provide evidence that the antiviral and conserved regions of IFN-tau disclosed in the references are responsible for the reduction in IFN-gamma blood levels in MS patients, Applicant would be enabled for the claimed method.

Finally, Applicants' disclosure regarding the peptide fragments of interferon-tau competing with interferon-alpha interactions for the type I interferon receptor is not relevant for enabling the claimed method because the claims of the instant application are drawn to a method having interferon-tau's interaction with interferon-gamma and not with interferon-alpha.

Conclusion

No claim is allowed.

All claims are drawn to the same invention claimed in the application prior to the entry of the submission under 37 CFR 1.114 and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Art Unit: 1647

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to IAN DANG whose telephone number is (571)272-5014. The examiner can normally be reached on Monday-Friday from 9am to 5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Manjunath Rao can be reached on (571) 272-0939. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Ian Dang
Patent Examiner
Art Unit 1647
June 1st, 2009

/Robert Landsman/
Primary Examiner, Art Unit 1647